An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neckVassiliki Saloura, Thomas Gauler, Salem Billan et al.|Cancer Chemotherapy and Pharmacology|2014Cited by 87
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.Vassiliki Saloura, Thomas Gauler, Ezra E.W. Cohen et al.|Journal of Clinical Oncology|2013Cited by 3
Moving from 2D to 3D conformal radiotherapy (3DCRT) in locally advanced head and neck cancer: A dosimetric comparisonSalem Billan, Abraham Kuten, Ron Epelbaum et al.|Journal of Clinical Oncology|2007Cited by 1